Pharma company Merck has agreed to lower the price of HIV med efavirenz (known as Sustiva in the U.S.) by 14% in developing countries. Merck said the price cut was made by possible by improvements in manufacturing efficiency.
A Merck Price Cut
Pharma company Merck has agreed to lower the price of HIV med efavirenz (known as Sustiva in the U.S.) by 14% in developing countries. Merck said the price cut was made by possible by improvements in manufacturing efficiency.
POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy
POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.
Comments
Comments